Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Earnings Data
Report Date
Apr 29, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.01Last Year’s EPS
0.64Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 10, 2025
|% Change Since: -22.12%
|Next Earnings Date:Apr 29, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth driven by products like Jakafi and Opzelura, significant progress in the pipeline with multiple FDA approvals, and a healthy financial position. However, challenges such as Medicare Part D dynamics, increased operating expenses, and potential pricing pressures were noted.Company Guidance
Incyte's guidance for 2025 emphasizes a strong financial outlook and robust pipeline development. The company projects Jakafi net product revenue to grow 5% to 7% year-over-year, reaching $2.925 to $2.975 billion, driven by demand growth, particularly in polycythemia vera (PV). Opzelura is expected to generate $630 to $670 million, reflecting a 24% to 32% increase, buoyed by continued growth in atopic dermatitis and vitiligo, as well as potential pediatric atopic dermatitis approval. Incyte anticipates four product launches in 2025, including Niktimvo, with these launches potentially contributing $1 billion in incremental revenues by 2029. The company ended 2024 with $2.2 billion in cash and no debt, underscoring its strong financial position to support the anticipated 18 key milestones and continued pipeline advancements.Strong Revenue Growth
2024 total revenues grew 15% versus 2023 to reach $4.2 billion. Jakafi net sales were $2.8 billion, growing 8% year-over-year.
Opzelura Performance
Opzelura revenue grew 50% to $508 million in 2024, driven by both new patients and refills in atopic dermatitis and vitiligo in the US, and expanding reimbursement outside the US.
Cash and Share Repurchase
Ended 2024 with $2.2 billion in cash and no debt. Completed a $2 billion share repurchase during 2024.
FDA Approvals and Pipeline Progress
FDA approved Niktimvo for chronic GVHD, and multiple other potential launches and approvals are expected in 2025, contributing potentially $1 billion in incremental revenues by 2029.
Pipeline Development
Plans to initiate at least three Phase 3 studies and expect four pivotal data readouts in 2025. Seven early-stage programs to generate informative data.
Strong Commercial Execution
Total revenues in Q4 2024 were $1.2 billion, up 16% versus the same period last year, driven by strong demand for Jakafi and Opzelura.
---
INCY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INCY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 10, 2025 | $74.13 | $68.30 | -7.86% |
| Oct 29, 2024 | $65.69 | $73.60 | +12.04% |
| Jul 30, 2024 | $68.59 | $67.79 | -1.17% |
| Apr 30, 2024 | $52.56 | $52.05 | -0.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Incyte Corp (INCY) report earnings?
Incyte Corp (INCY) is schdueled to report earning on Apr 29, 2025, TBA Not Confirmed.
What is Incyte Corp (INCY) earnings time?
Incyte Corp (INCY) earnings time is at Apr 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INCY EPS forecast?
INCY EPS forecast for the fiscal quarter 2025 (Q1) is 1.01.
---